AI-powered evaluation of lung function for diagnosis of interstitial lung disease

IF 9 1区 医学 Q1 RESPIRATORY SYSTEM
Thorax Pub Date : 2025-03-13 DOI:10.1136/thorax-2024-221537
Daniela Gompelmann, Maximilian Robert Gysan, Paul Desbordes, Julie Maes, Karolien Van Orshoven, Maarten De Vos, Markus Steinwender, Erich Helfenstein, Corina Marginean, Nicolas Henzi, Peter Cerkl, Patrick Heeb, Stephan Keusch, Gianluca Calderari, Paul von Boetticher, Bernhard Baumgartner, Daiana Stolz, Marioara Simon, Helmut Prosch, Wim Janssens, Marko Topalovic
{"title":"AI-powered evaluation of lung function for diagnosis of interstitial lung disease","authors":"Daniela Gompelmann, Maximilian Robert Gysan, Paul Desbordes, Julie Maes, Karolien Van Orshoven, Maarten De Vos, Markus Steinwender, Erich Helfenstein, Corina Marginean, Nicolas Henzi, Peter Cerkl, Patrick Heeb, Stephan Keusch, Gianluca Calderari, Paul von Boetticher, Bernhard Baumgartner, Daiana Stolz, Marioara Simon, Helmut Prosch, Wim Janssens, Marko Topalovic","doi":"10.1136/thorax-2024-221537","DOIUrl":null,"url":null,"abstract":"Background The diagnosis of interstitial lung disease (ILD) can pose a challenge as the pulmonary function test (PFT) is only minimally affected at the onset. To improve early diagnosis, this study aims to explore the potential of artificial intelligence (AI) software in assisting pulmonologists with PFT interpretation for ILD diagnosis. The software provides an automated description of PFT and disease probabilities computed from an AI model. Study methods In study phase 1, a cohort of 60 patients, 30 of whom had ILD, were retrospectively diagnosed by 25 pulmonologists (8 junior physicians and 17 experienced pneumologists) by evaluating a PFT (body plethysmography and diffusion capacity) and a short medical history. The experts screened the cohort twice, without and with the aid of AI (ArtiQ.PFT, V.1.4.0, ArtiQ, BE) software and provided a primary diagnosis and up to three differential diagnoses for each case. In study phase 2, 19 pulmonologists repeated the protocol after using ArtiQ.PFT for 4–6 months. Results Overall, AI increased the diagnostic accuracy for various lung diseases from 41.8% to 62.3% in study phase 1. Focusing on ILD, AI improved the detection of lung fibrosis as the primary diagnosis from 42.8% without AI to 72.1% with AI (p<0.0001). Phase 2 yielded a similar outcome: using AI increased ILD diagnosis based on primary diagnosis (53.2% to 75.1%; p<0.0001). ILD detections without AI support significantly increased between phase 1 and phase 2 (p=0.028) but not with AI (p=0.24). Interpretation This study shows that AI-based decision support on PFT interpretation improves accurate and early ILD diagnosis. All data relevant to the study are included in the article or uploaded as supplementary information.","PeriodicalId":23284,"journal":{"name":"Thorax","volume":"18 1","pages":""},"PeriodicalIF":9.0000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thorax","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/thorax-2024-221537","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background The diagnosis of interstitial lung disease (ILD) can pose a challenge as the pulmonary function test (PFT) is only minimally affected at the onset. To improve early diagnosis, this study aims to explore the potential of artificial intelligence (AI) software in assisting pulmonologists with PFT interpretation for ILD diagnosis. The software provides an automated description of PFT and disease probabilities computed from an AI model. Study methods In study phase 1, a cohort of 60 patients, 30 of whom had ILD, were retrospectively diagnosed by 25 pulmonologists (8 junior physicians and 17 experienced pneumologists) by evaluating a PFT (body plethysmography and diffusion capacity) and a short medical history. The experts screened the cohort twice, without and with the aid of AI (ArtiQ.PFT, V.1.4.0, ArtiQ, BE) software and provided a primary diagnosis and up to three differential diagnoses for each case. In study phase 2, 19 pulmonologists repeated the protocol after using ArtiQ.PFT for 4–6 months. Results Overall, AI increased the diagnostic accuracy for various lung diseases from 41.8% to 62.3% in study phase 1. Focusing on ILD, AI improved the detection of lung fibrosis as the primary diagnosis from 42.8% without AI to 72.1% with AI (p<0.0001). Phase 2 yielded a similar outcome: using AI increased ILD diagnosis based on primary diagnosis (53.2% to 75.1%; p<0.0001). ILD detections without AI support significantly increased between phase 1 and phase 2 (p=0.028) but not with AI (p=0.24). Interpretation This study shows that AI-based decision support on PFT interpretation improves accurate and early ILD diagnosis. All data relevant to the study are included in the article or uploaded as supplementary information.
基于ai的肺功能评估对间质性肺病的诊断价值
背景间质性肺疾病(ILD)的诊断具有挑战性,因为肺功能测试(PFT)在发病时仅受到最小的影响。为了提高早期诊断,本研究旨在探索人工智能(AI)软件在协助肺科医生通过PFT解释进行ILD诊断方面的潜力。该软件提供了PFT的自动描述和从人工智能模型计算的疾病概率。研究方法在第一阶段,一组60例患者,其中30例患有ILD,由25名肺科医生(8名初级医生和17名经验丰富的肺科医生)通过评估PFT(体体积脉搏图和弥散能力)和短病史进行回顾性诊断。专家们在人工智能(ArtiQ)的帮助下和在没有人工智能的情况下对这群人进行了两次筛选。PFT, V.1.4.0, ArtiQ, BE)软件,并为每个病例提供初步诊断和多达三个鉴别诊断。在研究第二阶段,19名肺科医生在使用ArtiQ后重复了该方案。PFT 4-6个月。结果总体而言,AI将各种肺部疾病的诊断准确率从41.8%提高到62.3%。在ILD中,AI将肺纤维化作为主要诊断的检出率从无AI的42.8%提高到有AI的72.1% (p<0.0001)。第二阶段的结果类似:使用人工智能增加了基于初级诊断的ILD诊断(53.2%至75.1%);p < 0.0001)。没有人工智能支持的ILD检测在第1期和第2期之间显著增加(p=0.028),但人工智能支持的ILD检测没有显著增加(p=0.24)。本研究表明,基于人工智能的PFT判读决策支持提高了ILD的准确和早期诊断。所有与研究相关的数据都包含在文章中或作为补充信息上传。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thorax
Thorax 医学-呼吸系统
CiteScore
16.10
自引率
2.00%
发文量
197
审稿时长
1 months
期刊介绍: Thorax stands as one of the premier respiratory medicine journals globally, featuring clinical and experimental research articles spanning respiratory medicine, pediatrics, immunology, pharmacology, pathology, and surgery. The journal's mission is to publish noteworthy advancements in scientific understanding that are poised to influence clinical practice significantly. This encompasses articles delving into basic and translational mechanisms applicable to clinical material, covering areas such as cell and molecular biology, genetics, epidemiology, and immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信